Standard BioTools
LAB
145 hedge funds and large institutions have $392M invested in Standard BioTools in 2020 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 54 increasing their positions, 32 reducing their positions, and 27 closing their positions.
101% more call options, than puts
Call options by funds: $5.23M | Put options by funds: $2.6M
69% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 32
41% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 27
8% more funds holding
Funds holding: 134 → 145 (+11)
4.66% less ownership
Funds ownership: 92.76% → 88.1% (-4.7%)
21% less capital invested
Capital invested by funds: $495M → $392M (-$104M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ICM
Indaba Capital Management
San Francisco,
California
|
+$10.3M |
| 2 |
Two Sigma Advisers
New York
|
+$3.84M |
| 3 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
+$3.72M |
| 4 |
PCMI
Paradigm Capital Management Inc
Albany,
New York
|
+$3.56M |
| 5 |
Two Sigma Investments
New York
|
+$3.45M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$13.8M |
| 2 |
EP
Eversept Partners
New York
|
-$9.68M |
| 3 |
Renaissance Technologies
New York
|
-$9.61M |
| 4 |
Millennium Management
New York
|
-$9.26M |
| 5 |
PVI
Pura Vida Investments
New York
|
-$6.04M |
LAB Hedge Fund Activity: Q4 2020 in Review
145 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2020, worth a combined $392M — down 21% from $495M a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new LAB positions and 27 closed out — a net gain of 11 holders — while 54 added to existing stakes and 32 trimmed.
The largest buyer was Indaba Capital Management, adding an estimated $10.3M. The largest seller was Invesco, cutting an estimated $13.8M.
- 145 institutional investors held Standard BioTools (LAB) as of Q4 2020, up from 134 in Q3 2020.
- Funds reported $392M of Standard BioTools stock for Q4 2020, down 21% quarter-over-quarter.
- 38 funds opened new Standard BioTools positions in Q4 2020 and 27 closed out, a net change of +11 holders.
- The largest Standard BioTools buyer in Q4 2020 was Indaba Capital Management, an estimated $10.3M added.
- The largest Standard BioTools seller in Q4 2020 was Invesco, an estimated $13.8M sold.
Based on aggregated 13F filings for Q4 2020.